Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE TVA Medical, Inc.
AUSTIN, Texas, Sept. 26, 2013 /PRNewswire/ -- Preliminary data presented last week at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual scientific meeting demonstrated that TVA Medical's FLEX System can create vascular access for hemodialysis patients without traditional open surgery. The technology is being studied outside of the United States and is currently not available in the U.S. The Company intends to seek Food and Drug Administration clearance in the future.
The study demonstrated that TVA Medical's vascular catheter-based FLEX System can create autogenous arterio-venous fistulas (AV fistulas) for hemodialysis patients with 94% procedural success.
Surgical AV fistulas are the current gold-standard for hemodialysis access, but they are plagued by high failure rates and frequent revisions resulting in enormous healthcare costs. Patients receiving surgical AV fistulas require an average of 2-3 additional interventions to achieve a usable fistula1, which can delay availability of the AV fistula for hemodialysis by 5-12 months2. Additionally, 30-60% of AV fistulas are never usable for dialysis, despite numerous re-interventions.1,3,4
"The preliminary results of this first in human study demonstrate that we can create usable autogenous AV fistulas without open surgery," said Dheeraj K. Rajan, MD, an investigator of the FLEX-1 study and Head of Vascular and Interventional Radiology at University of Toronto, Canada. "Moving to an entirely percutaneous procedure for vascular access has the potential to dramatically improve patient care by improving fistula usability, reducing surgical wait times, and reducing complications and costs."
"Overall, we are very pleased with the outcomes demonstrated in this clinical study," said Adrian Ebner, MD, principal investigator of the FLEX-1 study and Chief of Cardiovascular Services at the Italian Hospital, Asuncion, Paraguay. "Many of these patients were dependent on central venous catheters, and now have a functioning permanent vascular access delivered using a minimally-invasive procedure. I believe many patients worldwide will benefit from this procedure."
The FLEX-1 Pilot Study is a non-randomized, prospective study on the feasibility of using the FLEX System to create AV fistulas in patients with kidney failure requiring hemodialysis without open surgery. Sixteen patients were enrolled in the initial cohort and followed for 3 months. Additional follow-up is ongoing.
"Two million people worldwide rely on hemodialysis three times a week to sustain life, and many are subjected to multiple procedures and long duration on infection-prone catheters while they wait for a permanent workable AV fistula. There is an unmet need for a reliable, reproducible method to connect patients to the dialysis machine in a timely manner," said Adam L. Berman, CEO of TVA Medical. "We believe our technology has the potential to benefit hemodialysis patients around the world."
About the FLEX Catheter System
The TVA Medical FLEX system uses two vascular catheters, incorporating magnets and an RF electrode, that are delivered percutaneously to an artery and vein in the arm. When the catheters are magnetically aligned and positioned under fluoroscopy, RF energy is delivered to create an arteriovenous fistula without open surgery. No implant is left behind.
About End Stage Renal Disease and Hemodialysis
Over 2 million ESRD patients worldwide receive hemodialysis therapy and require vascular access to connect to a dialysis machine. CMS spends $47 billion annually to treat patients with end-stage renal disease. Vascular access is the leading cause of hospitalizations and morbidity in patients with end stage renal disease.5
About TVA Medical
TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease, including a catheter-based AV fistula system. The company was founded in 2008 by serial medical device entrepreneur and cardiovascular surgeon William (Billy) E. Cohn, MD, company CEO Adam L. Berman, and Sante Ventures. S3 Ventures led the Series B round in June 2013 that included TriStar Technology Ventures and Sante Ventures. www.TVAMedical.com
1 Peterson W., et al. Clin J Am Soc Nephol. 2008 March; 3(2):437-441.
2 Lee T., et al. Am J Kidney Dis. 2005 Sep;46(3):501-8.
3 Dember LM, et al. JAMA. 2008 May 14;299(18):2164-71.
4 Huijbregts HJ, et al. Clin J Am Soc Nephrol. 2008 May;3(3):714-9.
5 CMS Annual Report. End Stage Renal Disease Clinical Performance Measures Project. 2004.
©2012 PR Newswire. All Rights Reserved.